Superworth

Larimar Therapeutics price to book ratio LRMR

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026
1.9×
10-year median
1.7×
Against its 10-year history
55th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.4× to 8.3×
Peer median
2.2×

Larimar Therapeutics' price to book ratio is 1.9× as of Oct 23, 2026.

That is above its ten-year median of 1.7×, close to the middle of its last ten years.

Over that time it ranged from 0.4× in Sep 2019 to 8.3× in Sep 2018.

The median for 10 large drugmakers of a similar size is 2.2×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.9×1.6×6.5×
20252.4×0.7×3.6×
20241.3×1.3×6.8×
20232.2×1.1×2.4×
20221.5×0.5×2.3×
20212.7×1.6×3.9×
20203.2×0.5×3.7×
20190.7×0.4×1.9×
20181.8×1.7×8.3×
20171.4×0.8×1.4×
20160.7×0.5×1.3×
20150.9×0.8×10.3×
20146.5×3.1×6.5×

Against its peers

Companies in Drug Manufacturers - General nearest Larimar Therapeutics' size, closest first, today.

CompanyPrice to book ratio
LRMRLarimar Therapeutics1.9×
NATRNatures Sunshine Products1.3×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
LFVNLifevantage2.2×
ABUSArbutus Biopharma3.2×
SPROSpero Therapeutics1.5×
Peer median2.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Larimar Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.